Summary
The randomized phase 3 TNT trial, conducted to compare the efficacy of 2 chemotherapy drugs, carboplatin and docetaxel, at treating patients with advanced triple-negative breast cancer, showed that although survival outcomes were similar with both drugs, carboplatin was more efficacious in patients with BRCA1/2 gene mutations.
- estrogen receptor
- progesterone receptor
- HER2
- triple negative
- survival
- carboplatin
- docetaxel
- Triple Negative Breast Cancer Trial
- TNT
- NCT00532727
- © 2014 SAGE Publications